As BRD4 interacts with Cyclin-dependent Kinase 9 (CDK9) in other fusion-driven sarcomas, combinatorial treatment with BRD4 and CDK9 inhibitors may exert synergistic anti-tumor effects in PF+ RMS [205]. This evidence concerns the gene CDK9 and neoplasm.